Xeris Biopharma (XERS) Financials

$4.83 -0.05 (-1.02%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.90 +0.07 (+1.37%)

As of 05/23/2025 06:27 PM Eastern

Annual Income Statements for Xeris Biopharma

This table shows Xeris Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-55	-62	-95
Consolidated Net Income / (Loss)	-55	-62	-95
Net Income / (Loss) Continuing Operations	-55	-62	-95
Total Pre-Tax Income	-57	-64	-96
Total Operating Income	-34	-44	-82
Total Gross Profit	166	135	88
Total Revenue	203	164	110
Operating Revenue	203	164	110
Total Cost of Revenue	37	29	23
Operating Cost of Revenue	37	29	23
Total Operating Expenses	200	179	170
Selling, General & Admin Expense	163	146	138
Research & Development Expense	26	22	21
Amortization Expense	11	11	11
Total Other Income / (Expense), net	-23	-19	-14
Interest Expense	33	29	15
Interest & Investment Income	5.32	4.75	2.58
Other Income / (Expense), net	4.40	5.20	-1.40
Income Tax Expense	-2.27	-1.25	-1.42
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.00	0.00	-0.01
Basic Earnings per Share	($0.37)	($0.45)	($0.70)
Weighted Average Basic Shares Outstanding	146.77M	137.67M	135.63M
Diluted Earnings per Share	($0.37)	($0.45)	($0.70)
Weighted Average Diluted Shares Outstanding	146.77M	137.67M	135.63M
Weighted Average Basic & Diluted Shares Outstanding	153.94M	140.45M	137.29M

This table shows Xeris Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-9.22	-5.13	-16	-15	-19	-13	-12	-20	-17	-13	-22
Consolidated Net Income / (Loss)	-9.22	-5.11	-16	-15	-19	-13	-12	-20	-17	-13	-22
Net Income / (Loss) Continuing Operations	-9.22	-5.11	-16	-15	-19	-13	-12	-20	-17	-13	-22
Total Pre-Tax Income	-9.22	-5.11	-19	-14	-19	-14	-13	-21	-17	-13	-22
Total Operating Income	-3.09	1.68	-13	-8.19	-14	-9.84	-4.91	-16	-13	-15	-19
Total Gross Profit	51	51	41	40	35	29	40	38	28	27	24
Total Revenue	60	60	54	48	41	44	48	38	33	33	30
Operating Revenue	60	60	54	48	41	44	48	38	33	33	30
Total Cost of Revenue	8.73	9.48	14	7.79	5.97	15	8.20	0.00	5.32	6.29	5.26
Operating Cost of Revenue	8.73	9.48	14	7.79	5.97	-	8.20	-	5.32	6.29	5.26
Total Operating Expenses	54	49	54	48	49	39	45	54	41	42	43
Selling, General & Admin Expense	44	40	45	40	38	38	37	38	34	34	34
Research & Development Expense	7.75	6.09	5.89	5.76	7.82	6.38	5.03	6.09	4.84	4.96	6.04
Amortization Expense	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71
Total Other Income / (Expense), net	-6.13	-6.79	-6.17	-6.07	-4.43	-3.79	-7.61	-4.54	-3.56	1.90	-3.39
Interest Expense	7.31	7.70	7.79	7.96	9.72	7.02	9.68	6.53	6.22	4.37	3.99
Interest & Investment Income	1.18	0.91	1.20	1.29	1.92	1.11	1.12	1.22	1.30	1.84	0.47
Other Income / (Expense), net	0.00	0.00	0.42	0.60	3.37	2.13	0.95	0.77	1.36	4.43	0.13
Income Tax Expense	0.00	-	-3.32	0.75	0.31	-0.24	-0.34	-0.68	0.00	-0.34	-0.34
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.00	-	-0.02	-	-	-	-0.03	-	0.01	-	-0.02
Basic Earnings per Share	($0.06)	($0.02)	($0.11)	($0.10)	($0.14)	($0.10)	($0.09)	($0.14)	($0.12)	($0.10)	($0.16)
Weighted Average Basic Shares Outstanding	152.45M	146.77M	148.99M	148.35M	140.51M	137.67M	138.06M	137.34M	137.14M	135.63M	135.95M
Diluted Earnings per Share	($0.06)	($0.02)	($0.11)	($0.10)	($0.14)	($0.10)	($0.09)	($0.14)	($0.12)	($0.10)	($0.16)
Weighted Average Diluted Shares Outstanding	152.45M	146.77M	148.99M	148.35M	140.51M	137.67M	138.06M	137.34M	137.14M	135.63M	135.95M
Weighted Average Basic & Diluted Shares Outstanding	160.16M	153.94M	149.08M	149.00M	148.26M	140.45M	138.12M	138.07M	137.31M	137.29M	135.99M

This table details how cash moves in and out of Xeris Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	4.07	-55	59
Net Cash From Operating Activities	-37	-47	-103
Net Cash From Continuing Operating Activities	-37	-47	-103
Net Income / (Loss) Continuing Operations	-55	-62	-95
Consolidated Net Income / (Loss)	-55	-62	-95
Depreciation Expense	1.23	1.49	1.40
Amortization Expense	14	13	13
Non-Cash Adjustments To Reconcile Net Income	24	18	17
Changes in Operating Assets and Liabilities, net	-21	-17	-39
Net Cash From Investing Activities	4.88	-6.00	34
Net Cash From Continuing Investing Activities	4.88	-6.00	34
Purchase of Property, Plant & Equipment	-0.87	-2.26	-0.52
Purchase of Investments	-34	-44	0.00
Sale and/or Maturity of Investments	40	40	35
Net Cash From Financing Activities	36	-1.61	127
Net Cash From Continuing Financing Activities	36	-1.61	127
Repayment of Debt	-12	-1.19	-49
Issuance of Debt	50	0.00	146
Issuance of Common Equity	1.24	0.55	31
Other Financing Activities, net	-3.25	-0.98	-0.46
Cash Interest Paid	27	28	11

This table details how cash moves in and out of Xeris Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-13	12	1.53	-5.09	-4.76	21	-0.03	-4.74	-71	42	-11
Net Cash From Operating Activities	-10	1.98	-8.31	-10	-20	7.47	-15	-14	-26	-16	-18
Net Cash From Continuing Operating Activities	-10	1.98	-8.31	-10	-20	7.47	-15	-14	-26	-16	-18
Net Income / (Loss) Continuing Operations	-9.22	-5.11	-16	-15	-19	-13	-12	-20	-17	-13	-22
Consolidated Net Income / (Loss)	-9.22	-5.11	-16	-15	-19	-13	-12	-20	-17	-13	-22
Depreciation Expense	0.32	0.31	0.31	0.28	0.33	0.35	0.39	0.39	0.36	0.37	0.36
Amortization Expense	3.67	3.57	3.43	3.38	3.28	3.29	3.23	3.11	2.98	3.62	3.17
Non-Cash Adjustments To Reconcile Net Income	6.36	10	5.48	6.25	1.97	3.32	12	3.64	-0.68	-2.25	9.40
Changes in Operating Assets and Liabilities, net	-11	-7.05	-1.78	-5.26	-6.89	14	-18	-1.03	-12	-4.93	-9.05
Net Cash From Investing Activities	-0.01	10	9.91	4.60	-20	15	15	8.45	-44	9.17	6.71
Net Cash From Continuing Investing Activities	-0.01	10	9.91	4.60	-20	15	15	8.45	-44	9.17	6.71
Purchase of Property, Plant & Equipment	-0.01	-0.22	-0.09	-0.40	-0.16	-0.13	-0.35	-1.55	-0.24	-0.13	-0.18
Purchase of Investments	0.00	-	-5.00	-5.00	-24	-	-	-	-44	-	-
Sale and/or Maturity of Investments	0.00	10	15	10	5.00	15	15	10	0.00	9.30	6.89
Net Cash From Financing Activities	-3.14	0.40	-0.08	0.66	35	-1.23	-0.07	0.56	-0.86	49	-0.19
Net Cash From Continuing Financing Activities	-3.14	0.40	-0.08	0.66	35	-1.23	-0.07	0.56	-0.86	49	-0.19
Repayment of Debt	0.00	-	-	-	-12	-1.19	-	-	0.00	-0.06	-0.16
Issuance of Debt	0.00	-	-	-	50	-	-	-	0.00	49	-
Other Financing Activities, net	-3.14	-0.14	-0.08	-0.05	-2.98	-0.05	-0.07	0.01	-0.86	-0.02	-0.03
Cash Interest Paid	0.00	6.02	13	6.82	1.50	5.62	6.86	5.38	9.83	3.17	2.92

This table presents Xeris Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	323	323	345
Total Current Assets	168	156	187
Cash & Equivalents	72	67	122
Short-Term Investments	0.00	5.00	0.00
Accounts Receivable	40	39	31
Inventories, net	48	39	25
Prepaid Expenses	7.45	5.78	9.29
Plant, Property, & Equipment, net	5.56	5.97	5.52
Total Noncurrent Assets	150	160	152
Goodwill	23	23	23
Intangible Assets	99	110	121
Other Noncurrent Operating Assets	28	28	8.72
Total Liabilities & Shareholders' Equity	323	323	345
Total Liabilities	353	329	299
Total Current Liabilities	100	95	74
Short-Term Debt	15	19	0.00
Accounts Payable	2.29	12	4.61
Accrued Expenses	76	60	65
Other Current Liabilities	7.17	4.66	4.24
Total Noncurrent Liabilities	252	234	226
Long-Term Debt	217	191	187
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	2.27	3.52
Other Noncurrent Operating Liabilities	35	41	35
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-30	-6.78	45
Total Preferred & Common Equity	-30	-6.78	45
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-30	-6.78	45
Common Stock	642	610	600
Retained Earnings	-672	-617	-555
Accumulated Other Comprehensive Income / (Loss)	-0.03	-0.03	-0.02

This table presents Xeris Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	315	321	332	337	328	329	321	303
Total Current Assets	163	163	170	173	158	156	166	149
Cash & Equivalents	58	59	58	63	46	46	51	84
Accounts Receivable	46	41	42	37	46	30	31	28
Inventories, net	53	45	43	41	38	37	29	20
Prepaid Expenses	6.03	7.14	7.36	7.64	7.97	8.31	11	7.85
Plant, Property, & Equipment, net	5.26	5.61	5.83	5.78	6.19	6.55	6.48	5.75
Total Noncurrent Assets	147	153	156	158	164	166	149	148
Goodwill	23	23	23	23	23	23	23	23
Intangible Assets	96	102	104	107	112	115	118	123
Other Noncurrent Operating Assets	28	28	28	28	28	28	8.62	2.17
Total Liabilities & Shareholders' Equity	315	321	332	337	328	329	321	303
Total Liabilities	351	349	351	346	324	315	291	248
Total Current Liabilities	95	91	75	73	87	80	81	69
Short-Term Debt	12	15	0.42	1.02	18	17	15	-
Accounts Payable	6.35	7.45	5.80	7.09	12	12	12	3.92
Accrued Expenses	70	62	40	37	54	48	50	64
Other Current Liabilities	6.27	6.72	30	28	3.49	3.65	4.21	0.34
Total Noncurrent Liabilities	256	258	276	273	237	235	210	179
Long-Term Debt	218	216	230	230	190	188	188	139
Other Noncurrent Operating Liabilities	38	42	42	40	44	44	19	30
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-35	-28	-19	-9.18	3.87	14	30	55
Total Preferred & Common Equity	-35	-28	-19	-9.18	3.87	14	30	55
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-35	-28	-19	-9.18	3.87	14	30	55
Common Stock	646	638	632	627	608	605	602	597
Retained Earnings	-681	-667	-651	-636	-604	-591	-572	-542
Accumulated Other Comprehensive Income / (Loss)	-0.03	-0.02	-0.03	-0.04	-0.05	-0.08	-0.03	-0.04

This table displays calculated financial ratios and metrics derived from Xeris Biopharma's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	23.89%	48.68%	122.32%
EBITDA Growth	41.86%	64.15%	38.79%
EBIT Growth	24.63%	53.43%	28.07%
NOPAT Growth	23.55%	46.29%	28.84%
Net Income Growth	11.92%	34.23%	22.87%
EPS Growth	17.78%	35.71%	54.84%
Operating Cash Flow Growth	21.36%	54.30%	-7.70%
Free Cash Flow Firm Growth	53.98%	40.87%	50.26%
Invested Capital Growth	0.05%	18.60%	36.40%
Revenue Q/Q Growth	8.38%	7.37%	11.73%
EBITDA Q/Q Growth	40.16%	9.79%	37.36%
EBIT Q/Q Growth	24.31%	7.24%	31.50%
NOPAT Q/Q Growth	25.51%	10.80%	28.77%
Net Income Q/Q Growth	13.11%	-0.74%	28.57%
EPS Q/Q Growth	17.78%	0.00%	33.33%
Operating Cash Flow Q/Q Growth	-17.46%	33.41%	11.08%
Free Cash Flow Firm Q/Q Growth	-22.08%	36.05%	0.00%
Invested Capital Q/Q Growth	-2.01%	-10.30%	10.17%
Profitability Metrics	-	-	-
Gross Margin	81.86%	82.52%	79.47%
EBITDA Margin	-7.07%	-15.07%	-62.52%
Operating Margin	-16.57%	-26.85%	-74.32%
EBIT Margin	-14.40%	-23.68%	-75.59%
Profit (Net Income) Margin	-27.00%	-37.98%	-85.86%
Tax Burden Percent	96.03%	98.03%	98.52%
Interest Burden Percent	195.23%	163.63%	115.30%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-18.00%	-25.55%	-60.01%
ROIC Less NNEP Spread (ROIC-NNEP)	-38.99%	-56.58%	-207.03%
Return on Net Nonoperating Assets (RNNOA)	319.32%	-298.65%	-74.82%
Return on Equity (ROE)	301.32%	-324.20%	-134.83%
Cash Return on Invested Capital (CROIC)	-18.05%	-42.57%	-90.80%
Operating Return on Assets (OROA)	-9.06%	-11.63%	-25.69%
Return on Assets (ROA)	-16.99%	-18.66%	-29.18%
Return on Common Equity (ROCE)	301.32%	-324.20%	-134.83%
Return on Equity Simple (ROE_SIMPLE)	185.16%	917.94%	-209.49%
Net Operating Profit after Tax (NOPAT)	-24	-31	-57
NOPAT Margin	-11.60%	-18.79%	-52.03%
Net Nonoperating Expense Percent (NNEP)	20.99%	31.03%	147.02%
Return On Investment Capital (ROIC_SIMPLE)	-11.63%	-15.16%	-24.70%
Cost of Revenue to Revenue	18.14%	17.48%	20.53%
SG&A Expenses to Revenue	80.50%	89.13%	124.94%
R&D to Revenue	12.59%	13.63%	19.02%
Operating Expenses to Revenue	98.43%	109.37%	153.79%
Earnings before Interest and Taxes (EBIT)	-29	-39	-83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-25	-69
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.00	4.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.49	1.98	1.64
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.09	3.53	2.23
Enterprise Value to Revenue (EV/Rev)	3.28	2.82	2.23
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	-7.84	-30.97	4.14
Long-Term Debt to Equity	-7.33	-28.15	4.14
Financial Leverage	-8.19	5.28	0.36
Leverage Ratio	-17.74	17.37	4.62
Compound Leverage Factor	-34.63	28.42	5.33
Debt to Total Capital	114.63%	103.34%	80.54%
Short-Term Debt to Total Capital	7.46%	9.40%	0.00%
Long-Term Debt to Total Capital	107.17%	93.94%	80.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	-14.63%	-3.34%	19.46%
Debt to EBITDA	-16.16	-8.50	-2.71
Net Debt to EBITDA	-11.17	-5.57	-0.94
Long-Term Debt to EBITDA	-15.11	-7.73	-2.71
Debt to NOPAT	-9.86	-6.82	-3.26
Net Debt to NOPAT	-6.81	-4.47	-1.14
Long-Term Debt to NOPAT	-9.21	-6.20	-3.26
Altman Z-Score	-1.47	-1.75	-1.98
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.67	1.64	2.54
Quick Ratio	1.12	1.17	2.08
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-24	-51	-87
Operating Cash Flow to CapEx	-4,260.48%	-2,077.91%	-19,635.69%
Free Cash Flow to Firm to Interest Expense	-0.71	-1.74	-5.66
Operating Cash Flow to Interest Expense	-1.11	-1.60	-6.71
Operating Cash Flow Less CapEx to Interest Expense	-1.14	-1.67	-6.75
Efficiency Ratios	-	-	-
Asset Turnover	0.63	0.49	0.34
Accounts Receivable Turnover	5.10	4.68	4.57
Inventory Turnover	0.85	0.90	1.06
Fixed Asset Turnover	35.22	28.54	18.16
Accounts Payable Turnover	5.32	3.54	3.35
Days Sales Outstanding (DSO)	71.55	77.97	79.93
Days Inventory Outstanding (DIO)	431.14	405.03	345.53
Days Payable Outstanding (DPO)	68.65	103.03	109.09
Cash Conversion Cycle (CCC)	434.04	379.97	316.36
Capital & Investment Metrics	-	-	-
Invested Capital	131	131	110
Invested Capital Turnover	1.55	1.36	1.15
Increase / (Decrease) in Invested Capital	0.06	21	29
Enterprise Value (EV)	666	462	246
Market Capitalization	505	325	181
Book Value per Share	($0.20)	($0.05)	$0.33
Tangible Book Value per Share	($1.02)	($1.01)	($0.72)
Total Capital	202	203	232
Total Debt	232	210	187
Total Long-Term Debt	217	191	187
Net Debt	160	138	65
Capital Expenditures (CapEx)	0.87	2.26	0.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)	11	7.73	-8.77
Debt-free Net Working Capital (DFNWC)	82	80	113
Net Working Capital (NWC)	67	61	113
Net Nonoperating Expense (NNE)	31	31	37
Net Nonoperating Obligations (NNO)	160	138	65
Total Depreciation and Amortization (D&A)	15	14	14
Debt-free, Cash-free Net Working Capital to Revenue	5.27%	4.72%	-7.95%
Debt-free Net Working Capital to Revenue	40.54%	48.92%	102.67%
Net Working Capital to Revenue	33.10%	37.26%	102.67%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.37)	($0.45)	($0.70)
Adjusted Weighted Average Basic Shares Outstanding	146.77M	137.67M	135.63M
Adjusted Diluted Earnings per Share	($0.37)	($0.45)	($0.70)
Adjusted Weighted Average Diluted Shares Outstanding	146.77M	137.67M	135.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	153.94M	140.45M	137.29M
Normalized Net Operating Profit after Tax (NOPAT)	-24	-31	-57
Normalized NOPAT Margin	-11.60%	-18.79%	-52.03%
Pre Tax Income Margin	-28.12%	-38.74%	-87.15%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-0.88	-1.32	-5.44
NOPAT to Interest Expense	-0.71	-1.05	-3.74
EBIT Less CapEx to Interest Expense	-0.91	-1.39	-5.47
NOPAT Less CapEx to Interest Expense	-0.74	-1.12	-3.78
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Xeris Biopharma's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	47.94%	35.39%	12.31%	26.46%	22.42%	33.93%	62.56%	50.19%	50.39%	53.64%	168.76%
EBITDA Growth	112.34%	236.54%	-2,462.46%	66.55%	15.17%	39.69%	97.75%	40.44%	68.68%	85.89%	36.04%
EBIT Growth	71.58%	121.78%	-214.66%	50.15%	8.76%	28.19%	78.75%	34.63%	61.14%	78.10%	23.17%
NOPAT Growth	78.31%	117.06%	-162.43%	48.76%	-7.29%	35.13%	73.84%	15.53%	54.33%	68.57%	22.90%
Net Income Growth	51.42%	61.81%	-29.12%	24.38%	-12.75%	-3.56%	44.17%	24.22%	50.07%	74.54%	16.06%
EPS Growth	57.14%	80.00%	-22.22%	28.57%	-16.67%	0.00%	43.75%	26.32%	52.00%	77.78%	58.97%
Operating Cash Flow Growth	50.59%	-73.56%	43.16%	24.71%	22.33%	146.35%	17.71%	33.31%	46.00%	44.31%	21.48%
Free Cash Flow Firm Growth	36.55%	104.06%	106.60%	95.91%	85.27%	31.58%	55.74%	57.33%	63.31%	0.00%	-476.50%
Invested Capital Growth	1.51%	0.05%	-8.41%	-2.72%	-2.44%	18.60%	45.66%	37.16%	34.90%	36.40%	4,425.95%
Revenue Q/Q Growth	0.03%	10.74%	12.91%	18.28%	-8.45%	-8.13%	27.13%	14.50%	0.16%	11.50%	17.46%
EBITDA Q/Q Growth	-83.88%	163.68%	-122.91%	46.09%	-78.43%	-1,095.01%	97.09%	-36.74%	-26.85%	55.33%	23.13%
EBIT Q/Q Growth	-283.93%	113.47%	-64.49%	30.26%	-40.95%	-94.63%	73.94%	-27.64%	-10.93%	42.40%	19.84%
NOPAT Q/Q Growth	-284.04%	113.02%	-57.48%	42.53%	-44.75%	-100.31%	69.25%	-20.35%	12.48%	19.22%	0.72%
Net Income Q/Q Growth	-80.32%	67.51%	-4.89%	20.94%	-41.75%	-9.85%	38.57%	-17.87%	-30.19%	40.77%	16.63%
EPS Q/Q Growth	-200.00%	81.82%	-10.00%	28.57%	-40.00%	-11.11%	35.71%	-16.67%	-20.00%	37.50%	15.79%
Operating Cash Flow Q/Q Growth	-607.90%	123.78%	19.74%	49.03%	-371.76%	151.14%	-6.30%	47.42%	-62.17%	9.21%	13.85%
Free Cash Flow Firm Q/Q Growth	-477.40%	-65.76%	263.45%	69.95%	75.88%	44.26%	-1.31%	-8.12%	-12.05%	63.93%	2.33%
Invested Capital Q/Q Growth	4.07%	-2.01%	-0.36%	-0.09%	2.57%	-10.30%	5.83%	0.19%	24.69%	10.17%	-0.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	85.48%	84.23%	74.95%	83.79%	85.31%	65.93%	83.03%	100.00%	83.98%	81.02%	82.30%
EBITDA Margin	1.49%	9.26%	-16.10%	-8.16%	-17.89%	-9.18%	-0.71%	-30.84%	-25.82%	-20.39%	-50.88%
Operating Margin	-5.14%	2.79%	-23.76%	-17.03%	-35.05%	-22.17%	-10.17%	-42.04%	-40.00%	-45.77%	-63.18%
EBIT Margin	-5.14%	2.80%	-22.98%	-15.78%	-26.76%	-17.38%	-8.20%	-40.02%	-35.90%	-32.42%	-62.75%
Profit (Net Income) Margin	-15.34%	-8.51%	-29.00%	-31.22%	-46.71%	-30.16%	-25.23%	-52.20%	-50.71%	-39.01%	-73.44%
Tax Burden Percent	100.00%	100.00%	82.56%	105.25%	101.64%	98.27%	97.30%	96.71%	100.00%	97.45%	98.47%
Interest Burden Percent	298.38%	-304.35%	152.83%	188.00%	171.72%	176.62%	316.02%	134.87%	141.25%	123.49%	118.85%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-5.92%	3.04%	-22.31%	-15.91%	-30.95%	-21.10%	-8.84%	-33.12%	-28.38%	-36.96%	-85.30%
ROIC Less NNEP Spread (ROIC-NNEP)	-10.41%	-1.18%	-26.72%	-22.60%	-38.13%	-27.52%	-18.19%	-44.61%	-41.73%	-46.06%	-120.21%
Return on Net Nonoperating Assets (RNNOA)	73.92%	9.70%	332.00%	1,110.84%	-458.31%	-145.22%	-57.77%	-76.75%	-37.26%	-16.65%	-113.74%
Return on Equity (ROE)	68.00%	12.73%	309.69%	1,094.93%	-489.26%	-166.32%	-66.60%	-109.87%	-65.64%	-53.60%	-199.04%
Cash Return on Invested Capital (CROIC)	-13.15%	-18.05%	-13.85%	-16.40%	-20.70%	-42.57%	-65.26%	-68.48%	-68.38%	-90.80%	0.00%
Operating Return on Assets (OROA)	-3.51%	1.76%	-13.27%	-8.67%	-13.94%	-8.54%	-3.97%	-16.58%	-13.22%	-11.02%	-28.52%
Return on Assets (ROA)	-10.47%	-5.35%	-16.75%	-17.15%	-24.33%	-14.82%	-12.21%	-21.62%	-18.68%	-13.26%	-33.38%
Return on Common Equity (ROCE)	68.00%	12.73%	309.69%	1,094.93%	-489.26%	-166.32%	-66.60%	-109.87%	-65.64%	-53.60%	-199.04%
Return on Equity Simple (ROE_SIMPLE)	128.32%	0.00%	222.83%	308.85%	701.69%	0.00%	-1,598.84%	-523.69%	-258.85%	0.00%	-240.77%
Net Operating Profit after Tax (NOPAT)	-2.16	1.18	-9.03	-5.73	-9.97	-6.89	-3.44	-11	-9.29	-11	-13
NOPAT Margin	-3.60%	1.96%	-16.63%	-11.92%	-24.54%	-15.52%	-7.12%	-29.43%	-28.00%	-32.04%	-44.23%
Net Nonoperating Expense Percent (NNEP)	4.49%	4.22%	4.42%	6.68%	7.18%	6.41%	9.36%	11.49%	13.35%	9.11%	34.92%
Return On Investment Capital (ROIC_SIMPLE)	-1.11%	0.58%	-	-	-	-3.39%	-	-	-	-4.57%	-
Cost of Revenue to Revenue	14.52%	15.77%	25.05%	16.21%	14.69%	34.07%	16.97%	0.00%	16.02%	18.98%	17.70%
SG&A Expenses to Revenue	73.22%	66.79%	82.86%	83.21%	94.44%	84.63%	77.17%	99.02%	101.23%	103.66%	116.03%
R&D to Revenue	12.90%	10.14%	10.85%	11.98%	19.25%	14.38%	10.42%	16.02%	14.57%	14.95%	20.33%
Operating Expenses to Revenue	90.62%	81.44%	98.71%	100.83%	120.36%	88.10%	93.20%	142.04%	123.97%	126.79%	145.48%
Earnings before Interest and Taxes (EBIT)	-3.09	1.68	-12	-7.58	-11	-7.72	-3.96	-15	-12	-11	-19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.90	5.56	-8.74	-3.92	-7.27	-4.08	-0.34	-12	-8.57	-6.76	-15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	66.44	26.37	7.45	4.00	3.85
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.80	2.49	2.27	1.84	1.81	1.98	1.68	2.68	1.84	1.64	2.15
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.46	5.09	4.39	3.63	3.38	3.53	2.73	3.51	2.41	2.23	2.57
Enterprise Value to Revenue (EV/Rev)	4.57	3.28	3.13	2.68	2.65	2.82	2.61	3.61	2.73	2.23	2.61
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-6.54	-7.84	-8.17	-11.97	-25.14	-30.97	53.80	15.02	6.74	4.14	2.52
Long-Term Debt to Equity	-6.20	-7.33	-7.63	-11.95	-25.02	-28.15	49.27	13.80	6.24	4.14	2.52
Financial Leverage	-7.10	-8.19	-12.42	-49.16	12.02	5.28	3.18	1.72	0.89	0.36	0.95
Leverage Ratio	-14.72	-17.74	-26.53	-117.01	31.53	17.37	10.71	7.39	5.21	4.62	8.26
Compound Leverage Factor	-43.91	53.99	-40.55	-219.97	54.14	30.68	33.84	9.97	7.36	5.71	9.82
Debt to Total Capital	118.05%	114.63%	113.95%	109.11%	104.14%	103.34%	98.18%	93.76%	87.08%	80.54%	71.56%
Short-Term Debt to Total Capital	6.14%	7.46%	7.42%	0.20%	0.46%	9.40%	8.27%	7.62%	6.43%	0.00%	0.00%
Long-Term Debt to Total Capital	111.90%	107.17%	106.54%	108.92%	103.68%	93.94%	89.90%	86.14%	80.65%	80.54%	71.56%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-18.05%	-14.63%	-13.95%	-9.11%	-4.14%	-3.34%	1.82%	6.24%	12.92%	19.46%	28.44%
Debt to EBITDA	-37.08	-16.16	-9.64	-14.79	-9.86	-8.50	-7.59	-4.86	-4.04	-2.71	-1.26
Net Debt to EBITDA	-27.65	-11.17	-6.74	-9.82	-6.12	-5.57	-5.18	-2.94	-2.14	-0.94	-0.41
Long-Term Debt to EBITDA	-35.15	-15.11	-9.01	-14.77	-9.81	-7.73	-6.95	-4.46	-3.74	-2.71	-1.26
Debt to NOPAT	-14.59	-9.86	-7.32	-8.87	-7.33	-6.82	-6.02	-4.63	-4.38	-3.26	-1.72
Net Debt to NOPAT	-10.88	-6.81	-5.12	-5.89	-4.55	-4.47	-4.11	-2.81	-2.32	-1.14	-0.56
Long-Term Debt to NOPAT	-13.83	-9.21	-6.84	-8.85	-7.29	-6.20	-5.51	-4.25	-4.05	-3.26	-1.72
Altman Z-Score	-0.64	-1.16	-1.45	-1.36	-1.35	-1.43	-1.42	-1.30	-1.46	-1.28	-1.55
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.72	1.67	1.79	2.26	2.37	1.64	1.82	1.95	2.03	2.54	2.17
Quick Ratio	1.10	1.12	1.21	1.59	1.71	1.17	1.29	1.39	1.55	2.08	1.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.19	1.11	3.25	-1.99	-6.61	-27	-49	-49	-45	-40	-111
Operating Cash Flow to CapEx	-77,161.54%	897.73%	-9,545.98%	-2,606.55%	-12,379.88%	5,659.85%	-4,234.78%	-887.86%	-10,983.19%	-12,211.36%	-10,087.50%
Free Cash Flow to Firm to Interest Expense	-0.57	0.14	0.42	-0.25	-0.68	-3.90	-5.08	-7.43	-7.22	-9.17	-27.84
Operating Cash Flow to Interest Expense	-1.37	0.26	-1.07	-1.30	-2.09	1.06	-1.51	-2.11	-4.21	-3.69	-4.45
Operating Cash Flow Less CapEx to Interest Expense	-1.37	0.23	-1.08	-1.35	-2.11	1.05	-1.54	-2.34	-4.24	-3.72	-4.49
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.68	0.63	0.58	0.55	0.52	0.49	0.48	0.41	0.37	0.34	0.45
Accounts Receivable Turnover	5.32	5.10	4.30	4.99	5.02	4.68	4.16	4.79	4.48	4.57	4.80
Inventory Turnover	0.85	0.85	1.02	0.93	0.84	0.90	0.68	0.62	0.94	1.06	1.24
Fixed Asset Turnover	40.31	35.22	31.76	29.30	27.95	28.54	25.58	21.08	19.01	18.16	15.87
Accounts Payable Turnover	5.89	5.32	4.35	4.26	3.07	3.54	2.48	1.85	1.88	3.35	5.21
Days Sales Outstanding (DSO)	68.67	71.55	84.84	73.10	72.71	77.97	87.84	76.20	81.56	79.93	75.97
Days Inventory Outstanding (DIO)	431.34	431.14	357.71	391.28	435.53	405.03	536.73	588.77	386.47	345.53	293.37
Days Payable Outstanding (DPO)	61.98	68.65	83.90	85.72	118.84	103.03	147.34	197.45	194.23	109.09	70.06
Cash Conversion Cycle (CCC)	438.02	434.04	358.66	378.67	389.41	379.97	477.24	467.52	273.80	316.36	299.28
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	136	131	134	134	134	131	146	138	138	110	100
Invested Capital Turnover	1.65	1.55	1.34	1.33	1.26	1.36	1.24	1.13	1.01	1.15	1.93
Increase / (Decrease) in Invested Capital	2.03	0.06	-12	-3.75	-3.36	21	46	37	36	29	98
Enterprise Value (EV)	1,016	666	587	487	454	462	399	484	331	246	257
Market Capitalization	845	505	425	334	310	325	257	360	224	181	212
Book Value per Share	($0.23)	($0.20)	($0.19)	($0.13)	($0.07)	($0.05)	$0.03	$0.10	$0.22	$0.33	$0.40
Tangible Book Value per Share	($1.00)	($1.02)	($1.03)	($0.99)	($0.99)	($1.01)	($0.95)	($0.91)	($0.81)	($0.72)	($0.67)
Total Capital	195	202	203	212	222	203	212	218	233	232	194
Total Debt	230	232	231	231	231	210	208	205	203	187	139
Total Long-Term Debt	218	217	216	230	230	191	190	188	188	187	139
Net Debt	171	160	162	153	143	138	142	124	107	65	45
Capital Expenditures (CapEx)	0.01	0.22	0.09	0.40	0.16	0.13	0.35	1.55	0.24	0.13	0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	22	11	17	18	14	7.73	23	12	3.95	-8.77	-13
Debt-free Net Working Capital (DFNWC)	80	82	87	95	101	80	89	93	99	113	80
Net Working Capital (NWC)	68	67	72	95	100	61	71	76	84	113	80
Net Nonoperating Expense (NNE)	7.06	6.29	6.71	9.27	9.01	6.50	8.75	8.66	7.54	2.31	8.69
Net Nonoperating Obligations (NNO)	171	160	162	153	143	138	142	124	107	65	45
Total Depreciation and Amortization (D&A)	3.99	3.88	3.74	3.66	3.60	3.64	3.62	3.49	3.35	3.99	3.53
Debt-free, Cash-free Net Working Capital to Revenue	9.86%	5.27%	9.31%	9.76%	8.09%	4.72%	14.77%	8.97%	3.25%	-7.95%	-13.25%
Debt-free Net Working Capital to Revenue	36.12%	40.54%	46.35%	52.52%	59.07%	48.92%	57.99%	69.14%	81.61%	102.67%	81.44%
Net Working Capital to Revenue	30.74%	33.10%	38.31%	52.29%	58.47%	37.26%	46.51%	56.73%	69.28%	102.67%	81.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.06)	($0.02)	($0.11)	($0.10)	($0.14)	($0.10)	($0.09)	($0.14)	($0.12)	($0.10)	($0.16)
Adjusted Weighted Average Basic Shares Outstanding	152.45M	146.77M	148.99M	148.35M	140.51M	137.67M	138.06M	137.34M	137.14M	135.63M	135.95M
Adjusted Diluted Earnings per Share	($0.06)	($0.02)	($0.11)	($0.10)	($0.14)	($0.10)	($0.09)	($0.14)	($0.12)	($0.10)	($0.16)
Adjusted Weighted Average Diluted Shares Outstanding	152.45M	146.77M	148.99M	148.35M	140.51M	137.67M	138.06M	137.34M	137.14M	135.63M	135.95M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	160.16M	153.94M	149.08M	149.00M	148.26M	140.45M	138.12M	138.07M	137.31M	137.29M	135.99M
Normalized Net Operating Profit after Tax (NOPAT)	-2.16	1.18	-9.03	-5.73	-9.97	-6.89	-3.44	-11	-9.29	-11	-13
Normalized NOPAT Margin	-3.60%	1.96%	-16.63%	-11.92%	-24.54%	-15.52%	-7.12%	-29.43%	-28.00%	-32.04%	-44.23%
Pre Tax Income Margin	-15.34%	-8.51%	-35.13%	-29.66%	-45.95%	-30.70%	-25.93%	-53.98%	-50.71%	-40.03%	-74.58%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.42	0.22	-1.60	-0.95	-1.12	-1.10	-0.41	-2.33	-1.92	-2.46	-4.68
NOPAT to Interest Expense	-0.30	0.15	-1.16	-0.72	-1.03	-0.98	-0.36	-1.71	-1.50	-2.43	-3.30
EBIT Less CapEx to Interest Expense	-0.42	0.19	-1.61	-1.00	-1.14	-1.12	-0.45	-2.57	-1.96	-2.49	-4.72
NOPAT Less CapEx to Interest Expense	-0.30	0.12	-1.17	-0.77	-1.04	-1.00	-0.39	-1.95	-1.53	-2.46	-3.34
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Xeris Biopharma's Financials

When does Xeris Biopharma's financial year end?

According to the most recent income statement we have on file, Xeris Biopharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Xeris Biopharma's net income changed over the last 2 years?

Xeris Biopharma's net income appears to be on a downward trend, with a most recent value of -$54.84 million in 2024, falling from -$94.66 million in 2022. The previous period was -$62.26 million in 2023. View Xeris Biopharma's forecast to see where analysts expect Xeris Biopharma to go next.

What is Xeris Biopharma's operating income?

Xeris Biopharma's total operating income in 2024 was -$33.65 million, based on the following breakdown:

Total Gross Profit: $166.24 million
Total Operating Expenses: $199.88 million

How has Xeris Biopharma revenue changed over the last 2 years?

Over the last 2 years, Xeris Biopharma's total revenue changed from $110.25 million in 2022 to $203.07 million in 2024, a change of 84.2%.

How much debt does Xeris Biopharma have?

Xeris Biopharma's total liabilities were at $352.68 million at the end of 2024, a 7.1% increase from 2023, and a 17.8% increase since 2022.

How much cash does Xeris Biopharma have?

In the past 2 years, Xeris Biopharma's cash and equivalents has ranged from $67.45 million in 2023 to $121.97 million in 2022, and is currently $71.62 million as of their latest financial filing in 2024.

How has Xeris Biopharma's book value per share changed over the last 2 years?

Over the last 2 years, Xeris Biopharma's book value per share changed from 0.33 in 2022 to -0.20 in 2024, a change of -159.8%.

Related Companies

This page (NASDAQ:XERS) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Financials

Frequently Asked Questions About Xeris Biopharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Financials

Annual Income Statements for Xeris Biopharma

Quarterly Income Statements for Xeris Biopharma

Annual Cash Flow Statements for Xeris Biopharma

Quarterly Cash Flow Statements for Xeris Biopharma

Annual Balance Sheets for Xeris Biopharma

Quarterly Balance Sheets for Xeris Biopharma

Annual Metrics And Ratios for Xeris Biopharma

Quarterly Metrics And Ratios for Xeris Biopharma

Frequently Asked Questions About Xeris Biopharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools